Grace Therapeutics Inc. (GRCE)
Market Closed
27 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
2. 30
-0.03
-1.2876%
$
38.57M Market Cap
- P/E Ratio
- Div Yield
116,092 Volume
0 Eps
$ 2.33
Previous Close Investors:
Want to track GRCE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Grace Therapeutics: Assessing The Path Forward For GTx-104
Grace Therapeutics is rated a Speculative Buy with a $4 price target, implying 57% upside after a sharp drop from a CMC-only FDA CRL. The FDA's concerns for GTx-104 are limited to fixable chemistry, manufacturing, and controls issues, with no efficacy or safety objections raised. A scenario-weighted DCF model assigns a 75% probability of approval, forecasting $100M peak risk-adjusted U.S. sales and highlighting a favorable risk/reward profile.
Seekingalpha | 1 month ago
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
On Monday, Grace Therapeutics, Inc. GRCE, formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH).
Benzinga | 1 year ago
